BioSpace News Archive

By Biomarker Type, Safety Biomarkers Are Expected To Be The Maximum Revenue Generating Biomarker And Are Anticipated To Witness A Growth Of 15.9% During Forecast Period

Rise In Research And Development Projects In Various Regions Such As East Asia, South Asia Are Expected To Offer An Opportunity Of US $ 0.5 Bn In 2022-2026 Period.

The global asthma treatment market will rise from a value of ~US$ 25.6 Bn in 2019 to ~US$ 30.5 Bn by 2027, and it is anticipated that an increase in the number of FDA-approved products in parallel to the increasing awareness among asthma patients regarding quality care will drive the steady odyssey of the market.

The global chronic pancreatitis pain market is expected to witness strong growth during the forecast period between 2021 and 2031.

The global continuous renal replacement therapy (CRRT) market was valued at ~US$ 865 Mn in 2018. It is projected to expand at a high CAGR of ~7% from 2019 to 2027.

Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy.

Genomadix today announced it has entered into a know-how license agreement and stock purchase agreement with Mayo Clinic to advance its point of care molecular analyzer technology.

Exanthema is a skin issue resulting in rashes and affects children.

The increasing incidence of cardiovascular ailments as well as certain chronic diseases such as cancer, is leading to considerable growth in the surgical procedures around the globe.

HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) are global health problems. As such, there is growing demand to improve the effectiveness and simplify tests for HIV diagnostics, without compromising on the patient’s quality of life.